Scinai Immunotherapeutics Reports Remarkable Growth and Development in 2025 Financial Results Scinai Immunotherapeutics has showcased a significant leap in CDMO revenues and strategic collaborations in its latest financial results.

Scinai Immunotherapeutics Reports Remarkable Growth and Development in 2025 Financial Results #Israel #Jerusalem #Scinai #PC111 #Recipharm

Scinai Immunotherapeutics Faces Nasdaq Minimum Bid Price Notification Scinai Immunotherapeutics Ltd. has received a notification from Nasdaq regarding its non-compliance with minimum bid price rules, allowing them time to comply.

Scinai Immunotherapeutics Faces Nasdaq Minimum Bid Price Notification #NASDAQ #Israel #Jerusalem #Biopharmaceutical #Scinai

Scinai Immunotherapeutics Gains Clearance from Italy for Pincell Acquisition Scinai Immunotherapeutics has received regulatory clearance in Italy for the acquisition of Pincell S.r.l., marking a significant step in its growth strategy in biotechnology.

Scinai Immunotherapeutics Gains Clearance from Italy for Pincell Acquisition #Italy #Jerusalem #Immunotherapy #Scinai #Pincell

Scinai Immunotherapeutics Reports Promising Q1 2025 Results with Growth in CDMO Revenue Scinai Immunotherapeutics has announced its Q1 2025 financial results, showing strong revenue growth in its CDMO services and reduced cash burn. The company is focused on innovative drug development.

Scinai Immunotherapeutics Reports Promising Q1 2025 Results with Growth in CDMO Revenue #Israel #Jerusalem #Immunotherapy #Scinai #CDMO

Scinai to Acquire Pincell and Advance Development of Groundbreaking Monoclonal Antibody Scinai confirms its acquisition of Pincell, focusing on a novel antibody for treating severe dermatological conditions and advancing its development with a significant grant application.

Scinai to Acquire Pincell and Advance Development of Groundbreaking Monoclonal Antibody #Israel #Jerusalem #Scinai #Pincell #PC111

Dr. Jonathan Sadeh Joins Scinai Immunotherapeutics Scientific Board to Advance Innovative Treatments Dr. Jonathan Sadeh has been appointed to Scinai Immunotherapeutics' Scientific Advisory Board, promising advancements in immunology treatments.

Dr. Jonathan Sadeh Joins Scinai Immunotherapeutics Scientific Board to Advance Innovative Treatments #Israel #Jerusalem #Immunotherapy #Scinai #Jonathan_Sadeh